Humacyte, Inc. announced that it will deliver five podium presentations at the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) in November 2025. The presentations centre on its acellular tissue‑engineered vessel (ATEV™) and provide comprehensive clinical and histologic data across multiple indications.
Key highlights include a histologic analysis of ATEV implants up to 200 weeks post implantation, demonstrating progressive recellularization by host smooth muscle and endothelial cells—effectively converting the implanted conduit into a living, multi‑layered vascular tissue. Another presentation reports durable patency and freedom from graft‑related infection or rupture in patients treated for dialysis access–associated steal syndrome (DRIL procedures) with follow‑up up to 35.9 months.
Additional data cover durable two‑year outcomes in trauma patients treated in wartime extremity settings using ATEV (17 patients with 100% limb‑salvage and zero conduit infections) and a 24‑month patency comparison in female dialysis patients showing superior performance versus autologous arteriovenous fistula in a randomized subgroup. A case‑report presentation also details ATEV use in torso arterial trauma, expanding potential vascular applications.
These datasets reinforce Humacyte’s positioning of ATEV as a versatile, off‑the‑shelf bioengineered solution with broad potential across traumatic, dialysis‑access and potentially coronary indications. While ATEV is already approved by the U.S. FDA for an extremity vascular trauma indication, all other applications remain investigational and are advancing toward regulatory filings.
